Member Directory
Isomerase is a synthetic biology and bioprocess innovation partner helping companies develop new products or processes through harnessing bacteria and fungi to discover and produce native or novel molecules sustainably, cost effectively and at scale. We engineer microbial strains, develop then improve production processes using upstream and downstream process development at our bioprocess facility and help partners tech transfer their process to scale. The three main products we work on are:
(1) Natural Products - we help partners to access and work with rare and hard-to-source natural products and producing strains, to produce novel analogues of microbial natural products and to scale-up their production.
(2) Recombinant Peptides – working in E. coli or Pichia we can develop scalable manufacturing processes designed to compete economically with synthetic processes, especially at scale.
(3) Biocatalytic Enzymes - we support the discovery and production of microbial enzymes for manufacture in our proprietary E. coli or Pichia systems and help to produce them at laboratory and pilot scale, to generate robust processes for their production and to tech transfer these processes to CDMOs enabling phase-appropriate larger scale manufacture.
Isomerase operates B2B with companies wanting to benefit from our microbial expertise to generate value in their products and progress their processes toward commercialisation. Isomerase has worked with companies throughout Europe and North America, ranging in size from two-person virtual operations to multinational companies serving a range of industries including pharmaceutical, diagnostic, agritech, consumer goods and functional materials.
We are one of the largest UK and European Patent and Trade Mark Attorney firms, with offices in London, Oxford, Cambridge, Paris and Munich. The breadth and depth of our technical knowledge relevant to patents is outstanding, with over 70 science and technology graduates in the firm including over 35 PhDs. No area of science or technology is outside our scope. Our trade marks team comprises senior professionals with backgrounds in major international law firms. The team has the expertise and resources to handle any trade marks matter. . . . We draft, file and prosecute patent and trade mark applications in the UK, Europe and the rest of the world. We handle patent oppositions and appeals within Europe, especially before the European Patent Office (EPO), and we can act to protect your patents throughout the world. We assist with cases before the UK Patents Courts and provide expert support for high-profile patent litigation in the UK and elsewhere. We advise on trade mark selection and strategy and we file, defend and oppose trade mark applications in the UK, Europe and the rest of the world. We can obtain global protection for your trade marks through international applications before the World Intellectual Property Organization (WIPO) and by instructing filing and prosecution programmes worldwide. We handle all aspects of design protection in the UK, Europe and the rest of the world.
All Partners have extensive experience, including senior executive positions in large pharmaceutical and entrepreneurial biotechnology companies. Their collective experience extends across business development and licensing, drug discovery and development, marketing, intellectual property management, venture capital and investment banking.. . Our client list ranges from small European start-ups through established US biotechs to large Japanese pharmaceutical companies. Kagulex Consulting provides a range of business and product development services including:. . -Global Product and Patent Licensing and Corporate Partnering. -Intellectual Property Strategy and Management. -Merger and Acquisition Advice and Due Diligence. -Pre-clinical Planning and Implementation. -Clinical and Regulatory Strategy Development and Implementation. -Strategic Business Plan Development. -Product and Technology Assessment. -Venture Facilitation
KELYON was founded in 2008 by a group of young and dynamic ICT and healthcare professionals who decided to put their knowledge and competencies together with the aim of improving the lives of patients and helping shape the future of healthcare around the world.. Due to our international experience in the healthcare sector, Kelyon stands as a certified and highly reliable supplier in the booming digital healthcare market, specialized in Software Medical Devices and with specific understanding and awareness of the increasing need for strict compliance to privacy and safety regulations regarding patient data. . Kelyon provides comprehensive and complete expertise in developing Software Medical Devices and eHealth applications for the prevention, diagnosis, and treatment of complex diseases, and offers complete and systematic guidance for SMD and e-Health app needs, covering all phases of the process, from concept development to final roll-out and maintenance, while complying to all regulatory requirements.
As the leading kidney research charity in the UK, nothing is going to stop us in our urgent mission to end kidney disease. We’re here to be heard, to make a difference, to change the future. This is a disease that ruins and destroys lives. It must be stopped.
Over the past 60 years, our research has made an impact. But kidney failure is rising, as are the factors contributing to it, such as diabetes and obesity.
Today, we are more essential than ever.
Kidney disease affects three million people in the UK, treatments can be gruelling and currently there is no cure. Only research will end this and nobody can do it but us, by offering kidney patients and their families hope for the future. We’re taking it on. But we can’t do it without you.
King's Business is responsible for driving innovation at King's College London. Through the development of new opportunities and partnerships we optimise the impact of research and create value for the College in its externally-facing activities. This includes securing partnerships with business and other sectors through diverse mechanisms such as patenting and licensing, the creation of spin-out companies, collaborative and contract research, consultancy and staff secondments to and from industry.
KISS - the multiplier agency.
An award-winning B2B marketing agency where expertise meets an unwavering desire for exceptional results. If you’re ambitious about multiplying the impact of your marketing performance, we are the agency to help your grow your business.
Fuelled by a team of experts across strategy, creativity, technology and performance, we will amplify your marketing performance and grow your business through our theory of multiplication: Creativity x Technology x Data.
We harness the power of creativity to ensure you stand out in the marketplace, enabling this with the latest technology. Everything we do is informed by data to deliver your message through the right channels, to the right audiences, at the right time to deliver maximum impact.
From concept to completion, our projects multiply results.
Growth is good. Multiplying is better.
Korecyte Bio is a preclinical biotech startup incorporated in 2023 in NL (Korecyte Bio BV) and in the UK (Korecyte Innovations Ltd.) The company has developed a genetic switching platform that can be fused to any CAR-based cell therapeutic, like CAR-T, as a stringent tumour-selective switch that can render the cells much safer and more effective in attacking a solid tumour.
Kymab is a biopharmaceutical company using a proprietary transgenic antibody platform, Kymouse, to discover and develop fully human monoclonal antibody drugs. The technology used to design the Kymouse strains originated from the Wellcome Trust Sanger Institute in Cambridge, UK. Kymouse™ has been designed to maximise the diversity of human antibodies produced in response to immunisation. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics.